Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Nucleotides Delivery for Cancer Treatment
share announcement

Nucleotides Delivery for Cancer Treatment

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 8632

Special Issue Editor

Dr. Anna Scomparin

E-Mail
Guest Editor
Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy
Interests: polymer therapeutics; nanomedicines; cancer therapy; nanovaccine

Special Issue Information

Dear Colleagues,  

The discovery of the RNA interference mechanism prompted the use of oligonucleotides as therapeutic agents for the treatment of several diseases, including cancer. Nevertheless, the peculiar physico-chemical features of the short RNA or DNA molecules and the complex physiopathology of tumour pose a hurdle to the efficacious delivery of oligonucleotides to cancer cells. To overcome these problems, scientists developed different types of carriers, such as viral vectors, exosomes, polymer- and lipid-based systems. Despite the big efforts and the design of several nanomedicines in preclinical and clinical investigations, the optimal formulation has yet to be found and remains an open challenge in pharmaceutical technology.  

This Special Issue aims to highlight novel approaches to the delivery of oligonucleotides to cancer, with attention to all the aspects of the nanomedicine development, from their synthesis and physico-chemical characterization, to the understanding of their biological properties and the in vivo efficacy. We are looking forward to receiving original research papers as well as review articles with expert opinion on the state of art and future perspective on the field. 

Dr. Anna Scomparin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • RNA interference
  • gene therapy
  • nanomedicine
  • polyplexes
  • lipoplexes
  • cancer therapy
  • receptor-mediate targeting
  • vasculature-dependent targeting

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2682 KiB  
Article
Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma
by Monica Argenziano, Federica Bessone, Chiara Dianzani, Marie Angèle Cucci, Margherita Grattarola, Stefania Pizzimenti and Roberta Cavalli
Pharmaceutics 2022, 14(2), 341; https://doi.org/10.3390/pharmaceutics14020341 - 31 Jan 2022
Cited by 17 | Viewed by 2523
Abstract
The siRNA-mediated inhibition of nuclear factor E2-related factor 2 (Nrf2) can be an attractive approach to overcome chemoresistance in various malignant tumors, including melanoma. This work aims at designing a new type of chitosan-shelled nanobubble for the delivery of siRNA against Nrf2 in [...] Read more.
The siRNA-mediated inhibition of nuclear factor E2-related factor 2 (Nrf2) can be an attractive approach to overcome chemoresistance in various malignant tumors, including melanoma. This work aims at designing a new type of chitosan-shelled nanobubble for the delivery of siRNA against Nrf2 in combination with an ultrasound. A new preparation method based on a water–oil–water (W/O/W) double-emulsion was purposely developed for siRNA encapsulation in aqueous droplets within a nanobubble core. Stable, very small NB formulations were obtained, with sizes of about 100 nm and a positive surface charge. siRNA was efficiently loaded in NBs, reaching an encapsulation efficiency of about 90%. siNrf2-NBs downregulated the target gene in M14 cells, sensitizing the resistant melanoma cells to the cisplatin treatment. The combination with US favored NB cell uptake and transfection efficiency. Based on the results, nanobubbles have shown to be a promising US responsive tool for siRNA delivery, able to overcome chemoresistance in melanoma cancer cells. Full article
(This article belongs to the Special Issue Nucleotides Delivery for Cancer Treatment)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 2075 KiB  
Review
Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model
by Sara Bozzer, Michele Dal Bo, Giuseppe Toffoli, Paolo Macor and Sara Capolla
Pharmaceutics 2021, 13(8), 1106; https://doi.org/10.3390/pharmaceutics13081106 - 21 Jul 2021
Cited by 6 | Viewed by 2750
Abstract
Oligonucleotide (ON) therapeutics are molecular target agents composed of chemically synthesized DNA or RNA molecules capable of inhibiting gene expression or protein function. How ON therapeutics can efficiently reach the inside of target cells remains a problem still to be solved in the [...] Read more.
Oligonucleotide (ON) therapeutics are molecular target agents composed of chemically synthesized DNA or RNA molecules capable of inhibiting gene expression or protein function. How ON therapeutics can efficiently reach the inside of target cells remains a problem still to be solved in the majority of potential clinical applications. The chemical structure of ON compounds could affect their capability to pass through the plasma membrane. Other key factors are nuclease degradation in the extracellular space, renal clearance, reticulo-endothelial system, and at the target cell level, the endolysosomal system and the possible export via exocytosis. Several delivery platforms have been proposed to overcome these limits including the use of lipidic, polymeric, and inorganic nanoparticles, or hybrids between them. The possibility of evaluating the efficacy of the proposed therapeutic strategies in useful in vivo models is still a pivotal need, and the employment of zebrafish (ZF) models could expand the range of possibilities. In this review, we briefly describe the main ON therapeutics proposed for anticancer treatment, and the different strategies employed for their delivery to cancer cells. The principal features of ZF models and the pros and cons of their employment in the development of ON-based therapeutic strategies are also discussed. Full article
(This article belongs to the Special Issue Nucleotides Delivery for Cancer Treatment)
►▼ Show Figures

Graphical abstract

26 pages, 1296 KiB  
Review
miRNAs as Therapeutic Tools and Biomarkers for Prostate Cancer
by Noemi Arrighetti and Giovanni Luca Beretta
Pharmaceutics 2021, 13(3), 380; https://doi.org/10.3390/pharmaceutics13030380 - 13 Mar 2021
Cited by 22 | Viewed by 2744
Abstract
Prostate cancer (PCa) is the fifth cause of tumor-related deaths in man worldwide. Despite the considerable improvement in the clinical management of PCa, several limitations emerged both in the screening for early diagnosis and in the medical treatment. The use of prostate-specific antigen [...] Read more.
Prostate cancer (PCa) is the fifth cause of tumor-related deaths in man worldwide. Despite the considerable improvement in the clinical management of PCa, several limitations emerged both in the screening for early diagnosis and in the medical treatment. The use of prostate-specific antigen (PSA)-based screening resulted in patients’ overtreatment and the standard therapy of patients suffering from locally advanced/metastatic tumors (e.g., radical prostatectomy, radiotherapy, and androgen deprivation therapy) showed time-limited efficacy with patients undergoing progression toward the lethal metastatic castration-resistant PCa (mCRPC). Although valuable alternative therapeutic options have been recently proposed (e.g., docetaxel, cabazitaxel, abiraterone, enzalutamide, and sipuleucel-T), mCRPC remains incurable. Based on this background, there is an urgent need to identify new and more accurate prostate-specific biomarkers for PCa diagnosis and prognosis and to develop innovative medical approaches to counteract mCRPC. In this context, microRNA (miRNAs) emerged as potential biomarkers in prostate tissues and biological fluids and appeared to be promising therapeutic targets/tools for cancer therapy. Here we overview the recent literature and summarize the achievements of using miRNAs as biomarkers and therapeutic targets/tools for fighting PCa. Full article
(This article belongs to the Special Issue Nucleotides Delivery for Cancer Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop